2. Search Result
Search Result
No matches for "

91056

" within the MedChemExpress (MCE) catalog. Here are the results you might be looking for.

7

Inhibitors & Agonists

6

Antibodies

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-110127
    NU9056
    Maximum Cited Publications
    6 Publications Verification

    		 Histone Acetyltransferase Apoptosis Cancer
    NU9056 is a potent and selective Tip60 (KAT5) histone acetyltransferase inhibitor with an of 2 µM. NU9056 shows >16-fold selectivity for Tip60 over PCAF, p300 and GCN5. NU9056 induces apoptosis of prostate cancer cells .
    NU9056
  • HY-19427A
    AZD9056 hydrochloride
    Maximum Cited Publications
    6 Publications Verification

    		 P2X Receptor Inflammation/Immunology
    AZD9056 hydrochloride is a selective orally active inhibitor of P2X7 which plays a significant role in inflammation and pain-causing diseases.
    AZD9056 hydrochloride
  • HY-108716
    Felezonexor

    CBS9106; SL-801

    		 CRM1 Apoptosis Cancer
    CBS9106 (SL-801) is a reversible oral CRM1 inhibitor with CRM1 degrading and antitumor activities. CBS9106, inhibits CRM1-dependent nuclear export, causing arrest of the cell cycle and inducing apoptosis in a time- and dose-dependent manner for a broad spectrum of cancer cells .
    Felezonexor
  • HY-120547
    UCB-11056

    		Adenylate Cyclase Neurological Disease Metabolic Disease
    UCB-11056 is a modulator of cyclic AMP generation. UCB-11056 can rapidly increase cyclic AMP levels in the rat brain in vivo and potentiate stimulated cyclic AMP formation in vitro. UCB-11056 does not stimulate cAMP formation on its own. UCB-11056 is a potential nootropic drug .
    UCB-11056
  • HY-U00227
    U91356

    		Dopamine Receptor Neurological Disease
    U91356 is a dopamine receptor agonist.
    U91356
  • HY-19427
    AZD9056

    		P2X Receptor Cancer
    AZD9056 is a P2X7 purinergic receptor antagonist with anticancer activity. AZD9056 can inhibit the invasion and metastasis of cancer stem cells .
    AZD9056
  • HY-135390
    Hydroxy desmethyl Bosentan

    Ro 64-1056

    		 Drug Metabolite Cardiovascular Disease
    Hydroxy desmethyl Bosentan (Ro 64-105) is a Bosentan metabolism produced by the cytochrome P450 enzymes CYP2C9 and CYP3A4 in the liver . Bosentan is a competitive and dual antagonist of endothelin-1 (ET) for the ETA and ETB receptors with Ki of 4.7 nM and 95 nM in human SMC, respectively. Bosentan can be used in treatment of pulmonary arterial hypertension .
    Hydroxy desmethyl Bosentan

Inquiry Online

Submit your filled information, we will contact you soon.

Salutation: * Country or Region:
* Applicant Name: * Organization Name:
* Department:    
* Email Address: * Product Name:
Cat. No.: * Requested quantity:
* Phone Number:    
Remarks:

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: